Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis
Top Cited Papers
- 15 July 2014
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 190 (2), 175-184
- https://doi.org/10.1164/rccm.201404-0703oc
Abstract
Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator recently approved for patients with CF age 6 and older with the G551D mutation. To evaluate ivacaftor in a postapproval setting and determine mechanism of action and response of clinically relevant markers. We conducted a longitudinal cohort study in 2012-2013 in G551D CF patients age 6 and older with no prior exposure to ivacaftor. Study assessments were performed at baseline, 1, 3, and 6 months after ivacaftor initiation. Substudies evaluated mucociliary clearance, β-adrenergic sweat secretion rate, gastrointestinal pH, and sputum inflammation and microbiology Measurements and Main Results: A total of 151 of 153 subjects were prescribed ivacaftor and 88% completed the study through 6 months. FEV1 % predicted improved from baseline to 6 months (mean absolute change, 6.7%; P < 0.001). Similarly, body mass index improved from baseline to 6 months (mean change, 0.8 kg/m(2); P < 0.001). Sweat chloride decreased from baseline to 6 months (mean change, -53.8 mmol/L; 95% confidence interval, -57.7 to -49.9; P < 0.001), reflecting augmented CFTR function. There was significant improvement in hospitalization rate (P < 0.001) and Pseudomonas aeruginosa burden (P < 0.01). Significant improvements in mucociliary clearance (P < 0.001), gastrointestinal pH (P = 0.001), and microbiome were also observed, providing clinical mechanisms underlying the therapeutic benefit of ivacaftor. Significant clinical and physiologic improvements were observed on initiation of ivacaftor in a broad patient population, including reduced infection with P. aeruginosa. Biomarker studies substantially improve the understanding of the mechanistic consequences of CFTR modulation on pulmonary and gastrointestinal physiology.Keywords
This publication has 35 references indexed in Scilit:
- Sixty-five years since the New York heat wave: Advances in sweat testing for cystic fibrosisPediatric Pulmonology, 2013
- Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator geneNature Genetics, 2013
- Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D MutationAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Gastrointestinal Complications of Cystic FibrosisClinical Gastroenterology and Hepatology, 2013
- Intractable cough in a preterm infant with ventriculoperitoneal shuntPediatric Pulmonology, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- Patient-reported respiratory symptoms in cystic fibrosisJournal of Cystic Fibrosis, 2009
- Development and Validation of the Cystic Fibrosis Questionnaire in the United StatesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2005
- Cystic FibrosisThe New England Journal of Medicine, 2005
- Cystic fibrosisThe Lancet, 2003